**Name of Journal:** *World Journal of Gastrointestinal Endoscopy*

**Manuscript NO:** 77930

**Manuscript Type:** ORIGINAL ARTICLE

***Prospective Study***

**Role of endoscopic ultrasound in evaluation of patients with missed common bile duct stones**

Eissa M *et al*. EUS evaluation of missed CBD stones

Mohamed Eissa, Hussein Hassan Okasha, Mohamed Abbasy, Ahmed Kamal Khamis, Abeer Abdellatef, Mohamed Akl Rady

**Mohamed Eissa, Mohamed Abbasy, Ahmed Kamal Khamis, Mohamed Akl Rady,** Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Menoufia 32951, Egypt

**Hussein Hassan Okasha, Abeer Abdellatef,** Department of Internal Medicine, Hepatogastroenterology Division, Kasr AL-Ainy School of Medicine, Cairo University, Cairo 11451, Egypt

**Author contributions:** Eissa M and Rady MA contributed equally in collecting the data and writing the manuscript; Abdellatef A read and revised the manuscript; Abbasy M and Kamal A read and approved the manuscript; Okasha HH revised and approved the final manuscript; all authors have read and approved the final manuscript.

**Corresponding author: Abeer Abdellatef, MD, Lecturer,** Department of Internal Medicine, Hepatogastroenterology Division, Kasr AL-Ainy School of Medicine, Cairo University, Kasr Al-Aini Street, Cairo 11451, Egypt. beero4a@yahoo.com

**Received:** June 2, 2022

**Revised:** July 26, 2022

**Accepted:** September 6, 2022

**Published online:** September 16, 2022

**Abstract**

BACKGROUND

Choledocholithiasis develops in up to 20% of patients with gall bladder stones. The challenge in diagnosis usually occurs with small stones that may be missed by magnetic resonance cholangiopancreatography (MRCP). Endoscopic ultrasound (EUS) is accurate in detecting common bile duct (CBD) stones missed by MRCP, especially the small ones or those impacted at the distal CBD or the papillary region.

AIM

To evaluate the accuracy of EUS in detecting CBD stones missed by MRCP.

METHODS

Patients with an intermediate likelihood of choledocholithiasis according to ESGE guidelines and those with acute pancreatitis of undetermined cause were included. The presence of choledocholithiasis was evaluated by MRCP and EUS, and then results were confirmed by endoscopic retrograde cholangiopancreatography (ERCP). The sensitivity and specificity of EUS and MRCP were compared regarding the presence of stones, the size, and the number of detected stones.

RESULTS

Ninety out of 100 involved patients had choledocholithiasis, while ten patients were excluded as they had pancreatic or gall bladder masses during EUS examination. In choledocholithiasis patients, the mean age was 52.37 ± 14.64 years, and 52.2% were males. Most patients had biliary obstruction (74.4%), while only 23 (25.6%) patients had unexplained pancreatitis. The overall prevalence of choledocholithiasis was 83.3% by EUS, 41.1% by MRCP, and 74.4% by ERCP. Also, the number and size of CBD stones could be detected accurately in 78.2% and 75.6% by EUS and 41.1% and 70.3% by MRCP, respectively. The sensitivity of EUS was higher than that of MRCP (98.51% *vs* 55.22%), and their predictive value was statistically different (*P <* 0.001). Combination of both tools raised the sensitivity to 97.22% and specificity to 100%.

CONCLUSION

EUS could be a useful tool in assessing patients with suspected choledocholithiasis especially if combined with MRCP. However, its usefulness depends on its availability and the experience of the local centers.

**Key Words:** Magnetic resonance cholangiopancreatography; Endoscopic ultrasonography; Choledocholithiasis; Missed common bile duct stones

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Eissa M, Okasha HH, Abbasy M, Khamis AK, Abdellatef A, Rady MA. Role of endoscopic ultrasound in evaluation of patients with missed common bile duct stones. *World J Gastrointest Endosc* 2022; 14(9): 564-574

**URL:** <https://www.wjgnet.com/1948-5190/full/v14/i9/564.htm>

**DOI:** https://dx.doi.org/10.4253/wjge.v14.i9.564

**Core Tip:** Still, there is a great challenge in diagnosing suspected cases of choledocholithiasis that could develop in up to 20% of patients with gall bladder stones. Endoscopic ultrasound (EUS) can easily detect small stones that magnetic resonance cholangiopancreatography (MRCP) could miss. EUS still has many diagnostic purposes with high accuracy in detecting common bile duct (CBD) stones missed by MRCP, especially the small ones or those impacted at the distal CBD or the papillary region.

**INTRODUCTION**

Choledocholithiasis is considered one of the most important causes of abdominal pain in patients with gall bladder stones. It can occur in 3%-16% of patients with gall stones and can reach up to 21% in patients with gall stone pancreatitis[1,2]. Diagnosis of choledocholithiasis is not always straightforward[3]. Clinical evaluation and biochemical tests are insufficient to establish a firm diagnosis without reliable confirmatory testing, so magnetic resonance cholangiopancreatography (MRCP) is routinely used to clarify the diagnosis after ultrasound results[4]. Endoscopic retrograde cholangiopancreatography (ERCP) is now considered the gold standard for diagnosis; however, its invasive nature and complications such as pancreatitis defer its use in diagnosis as a first option[5].

Since the recommendations by the ASGE and ESGE guidelines for diagnosing patients with an intermediate likelihood of choledocholithiasis by MRCP, endoscopic ultrasound (EUS) is now widely used to assess the presence of choledocholithiasis[6,7]. Despite its overall high accuracy, the role of EUS in the diagnosis of choledocholithiasis has not been firmly established since EUS is relatively invasive compared with MRCP and computed tomography[8].

The cause of biliary obstruction is not always detected by the available non-invasive imaging modalities like MRCP and may be detected later during biliary drainage as small stones, so in our study, we evaluated the usefulness and accuracy of EUS in detecting missed stones by MRCP as a cause of biliary obstruction.

**MATERIALS AND METHODS**

***Methodology***

This observational cohort study aimed primarily to evaluate the usefulness and accuracy of EUS in detecting missed stones by MRCP as a cause of biliary obstruction.

***Patients and assessments***

This prospective study was conducted on 100 patients recruited from National Liver Institute and Internal Medicine Department, Kasr Al-Ainy Hospital from 2019 to 2021. We included patients with dilated CBD (diameter ranging from 6 to 10 mm), those with unexplained elevated liver enzymes, and those with unexplained causes of acute pancreatitis. All patients with cholangitis were excluded from the study and referred for urgent ERCP drainage. Also, we excluded patients with malignant masses found by EUS and confirmed by histopathology. All included patients were above 18 years of age.

Assessment of our patients was performed by liver function tests, serum amylase, lipase, abdominal ultrasound, MRCP, and EUS. ERCP was conducted on all patients for confirmation of the findings of MRCP and EUS. MRCP was done few days before EUS, then ERCP was done later on. The EUS operator was blind to MRCP examination. We followed up with the patients for 3 mo after the procedures clinically and biochemically.

Results from MRCP and EUS were compared with those from ERCP to calculate the sensitivity and specificity of EUS and MRCP in detecting choledocholithiasis in our patients. Also, the accuracy of both MRCP and EUS in detecting the size and number of stones in CBD was evaluated.

Our institution’s Research Ethical Committee approved the study, and all patients gave their informed written consent before inclusion in the study, according to the ethical guidelines of the 1975 Declaration of Helsinki.

***Examination procedure***

All the patients, after thorough full history taking and clinical examination, were subjected to: (1) EUS examination using a linear Echoendoscope Pentax EG3870UTK (HOYA Corporation, PENTAX Life Care Division, Showanomori Technology Center, Tokyo, Japan) connected to a Hitachi AVIUS machine (Hitachi Medical Systems, Tokyo, Japan). All examinations were performed under deep sedation with IV propofol. For EUS-FNA, we used the Cook 19G and 22G needles (Echotip; Wilson-Cook, Winston Salem, NC). Prophylactic ceftriaxone (1 g) was administrated before the procedure; and (2) ERCP examination that was performed using a side view scope Pentax ED-3490TK (HOYA Corporation, Tokyo, Japan). All examinations were performed under deep sedation with IV propofol. Prophylactic ceftriaxone (1 g) was administrated before the procedure.

***Statistical analysis***

Data were fed to the computer and analyzed using IBM SPSS software version 20.0 (Armonk, NY: IBM Corp). Qualitative data are described using numbers and percentages. The Kolmogorov-Smirnov test was used to verify the normality of distribution. Quantitative data are described using range (minimum and maximum), mean, standard deviation, median, and interquartile range. The significance of the obtained results was judged at the 5% level. The chi-square test was applied to compare categorical variables between different groups. The Fisher’s exact test was used for correction for chi-square when more than 20% of the cells had an expected count of less than 5.

**RESULTS**

After excluding the ten patients with malignancy, the total number of male patients was 47 (52%), and that of female patients was 43 (48%), who were included till the end of the study with a mean age of 52.37 ± 14.64 years (Figure 1). The number of patients who fulfilled the criteria of an intermediate probability of biliary obstruction were 67 (74.4%), while that of patients with unexplained acute pancreatitis was 23 (25.6%). Only seven patients proved to have CBD stones, of whom all were detected by EUS, but only four were detected by MRCP. No other causes of acute pancreatitis as cystic pancreatic lesions, pancreatic divisum, or pancreatic duct stones could be detected by MRCP or EUS. Most patients had elevated liver enzymes (60%) and direct hyperbilirubinemia (81%), as shown in Table 1. Abdominal ultrasound showed that 72.2% of patients had gall bladder stones; meanwhile, only nine had a history of cholecystectomy with a mean CBD diameter of 9.13 ± 2.35 mm (Figure 2).

Choledocholithiasis was detected in 83.3% of patients by EUS, 74.4% by ERCP but only 41.1% by MRCP. EUS detected the number of stones more accurately than MRCP (95% *vs* 41%, respectively), as shown in Table 2.

Regarding the size of stones, EUS had a higher accuracy in detecting stones less than 5 mm (25 out of 53 negatives for stones by MRCP), as shown in Table 2.

EUS was statistically more accurate than MRCP in detecting stones (*P* < 0.001), especially in stones less than 5 mm (88.8% *vs* 66.6%, respectively). The sensitivity of EUS was 98.51%, while that of MRCP was only 55.5%, but the specificity of MRCP was higher than that of EUS (100% *vs* 60.87%, respectively), as shown in Table 3. The combination of EUS with MRCP showed a sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and overall accuracy of 97.22%, 100%, 100%, 91.67%, and 97.87%, respectively (Table 4).

Indeed, there are differences in endoscopic skill between endoscopists, so we analyzed the data for expert and non-expert endoscopists (Table 5).

We found ten cases considered false negative by EUS, where six cases had gravels on EUS, three had small non-floating stones less than 5 mm, and one had a stone over the old plastic stent. Figures 3-5 show different forms of detected CBD stones from our patients.

The ten cases with the malignant cause of biliary obstruction were detected by EUS as seven cases with pancreatic head mass, two with gall bladder carcinoma, and one with CBD mass (diagnosed as cholangiocarcinoma by further evaluation with spyglass).

**DISCUSSION**

MRCP has been used to detect biliary obstruction in the last decade, but the cause cannot be detected in many patients[5]. The latest ASGE and ESGE guidelines recommend performing MRCP or EUS for evaluating patients with an intermediate probability of choledocholithiasis. However, it does not recommend one modality over the other[6,7]. Since the wide use of EUS, many studies have evaluated its role in detecting the cause of biliary obstruction[8]. EUS has a high accuracy in diagnosing pancreatic diseases and sampling tissues, but its role in diagnosing choledocholithiasis has not been confirmed like in pancreatic diseases[9].

This study evaluated the accuracy of EUS in detecting CBD stones, especially those missed by MRCP in patients with an intermediated probability of CBD stones and recurrent unexplained pancreatitis. Our study included 100 patients, which is considered a large number compared to other studies like Rana *et al*[10] (40 patients) and Patel *et al*[11] (78 patients), but a small number compared to Wee *et al*[12] who included 593 patients but only 35.3% of those patients had MRCP (all our patients had MRCP).

Similar to the previously mentioned studies[10,11], we found no statistically significant variables regarding clinical and laboratory data that could predict the presence of CBD stones on EUS, MRCP, or ERCP.

In the current study, we found that EUS had a higher accuracy in detecting choledocholithiasis than MRCP (88.8% *vs* 66.6%, respectively) with a higher sensitivity (98% *vs* 55%, respectively) but lower specificity (60.8% *vs* 100%, respectively). This lower specificity of EUS might be attributed to the time gap between EUS and ERCP (passed stones), missed gravels during balloon sweeping, and false perception of air as stones in some cases. Many other studies that evaluated the diagnosis of choledocholithiasis by EUS showed variable results regarding sensitivities and specificities. For example*,* Jagtap *et al*[13] showed that the sensitivities of both EUS and MRCP were similarly high (92%-98%). Also, Patel *et al*[11] showed that the sensitivity and specificity of EUS were 93% and 97.3%, respectively, but most included patients had a high probability of choledocholithiasis. Wee *et al*[12] reported sensitivities from 85% to 100% for EUS and 73% to 99% for MRCP. In a meta-analysis of five head-to-head studies comparing EUS to MRCP for choledocholithiasis, the pooled sensitivity and specificity of EUS were 97% and 90%, respectively, *vs* 87% and 92% for MRCP, respectively[14].

Also, de Lédinghen *et al*[15] reported a good sensitivity (100%) but low specificity (62%) for MRCP in diagnosing choledocholithiasis. Meanwhile, Materne *et al*[16] showed a 91% sensitivity and 94% specificity for MRCP, close to the values for EUS. The study conducted by Scheiman *et al*[17] reported significantly better results with EUS (sensitivity, 95%; specificity, 80%) than with MRCP (sensitivity, 40%; specificity, 96%) in diagnosing choledocholithiasis.

Another study compared the accuracy of EUS with ERCP in detecting choledocholithiasis and showed that EUS had a sensitivity of 100% and specificity of 94.7%.

One of the reasons for missed stones by MRCP that were detected by EUS was non-floating stones at the papillary region or distal CBD, as this is considered one of the pitfalls in MRCP interpretation, as mentioned by Irie *et al*[18]. Another reason was the stones with a diameter less than 5 mm (25 cases detected by EUS *vs* only 10 by MRCP), which suggests the accuracy of EUS in detecting small stones[19]. Also, EUS was superior to MRCP in detecting the number of stones inside the CBD (70 cases by EUS *vs* only 26 by MRCP), which is contradictory to the study of Aubé *et al*[20] that found no significant difference between the two modalities (MRCP detected four of six cases while EUS detected five of six cases).

Many studies comparing EUS and MRCP in idiopathic acute pancreatitis have shown that EUS has higher diagnostic yields than MRCP[21]. In this context, EUS should be considered the first choice in diagnosing idiopathic acute pancreatitis[22]. Biliary diseases such as cholelithiasis, choledocholithiasis, microlithiasis, and biliary sludge are the leading cause of idiopathic acute pancreatitis[23].

In our study, cases with unexplained pancreatitis were evaluated by EUS and MRCP, which showed that EUS was more sensitive in detecting stones than MRCP (90% *vs* 78%, respectively), as only seven patients proved to have CBD stones, of whom all were detected by EUS but only four were detected by MRCP[23]. Meanwhile, no other causes of acute pancreatitis as cystic pancreatic lesions, pancreatic divisum, or pancreatic duct stones could be detected by MRCP or EUS. And this finding is in agreement with Akkuzu *et al*[24], who reported a sensitivity of EUS and MRCP in evaluating acute pancreatitis of 89.65% and 72.4%, respectively.

Combining EUS with MRCP is very valuable in diagnosis of missed CBD stones than each one alone. In our study, the combination of the two tools raised the sensitivity, specificity, PPV, NPV, and overall accuracy into 97.22, 100, 100, 91.67, and 97.87, respectively.

The main limitation in our study was the financial cost of doing EUS, ERCP, and MRCP for all of the included patients. The second limitation was that we considered ERCP as the gold standard in detecting CBD stones. Although it is an accurate modality for detecting CBD stones, some false-negative cases may occur. Small stones may be missed if the CBD is under- or over-filling with contrast. Minute stones or gravels may be missed during balloon sweeping. Also, in some cases, there was a time gap between ERCP and EUS that might give a chance of passage of small stones out of the CBD that could give false-positive results on EUS.

**CONCLUSION**

Our study showed that EUS and MRCP are not equal tools in diagnosing choledocholithiasis in patients with an intermediate probability of choledocholithiasis. EUS is more accurate than MRCP in detecting non-floating stones in the papillary region and small stones, especially those less than 5 mm, and defining the size and number of stones. Furthermore, combining EUS with MRCP proved to be very valuable in accurate diagnosis of patients with an intermediate probability of choledocholithiasis.

EUS could be a good first option for evaluating patients with an intermediate probability of choledocholithiasis when it is available with good experience.

Combining EUS with MRCP is recommended for accurate evaluation of patients with an intermediate probability of choledocholithiasis if both are available.

**ARTICLE HIGHLIGHTS**

***Research background***

Choledocholithiasis develops in up to 20% of patients with gall bladder stones. The challenge in diagnosis usually occurs with small stones that may be missed by magnetic resonance cholangiopancreatography (MRCP). Endoscopic ultrasound (EUS) is accurate in detecting common bile duct (CBD) stones missed by MRCP, especially the small ones or those impacted at the distal CBD or the papillary region.

***Research motivation***

Still, there is a great challenge in diagnosing cases with an intermediate probability of choledocholithiasis that develop in up to 20% of patients with gall bladder stones. EUS can easily detect small stones that MRCP could miss. EUS still has many diagnostic purposes with a high accuracy in detecting CBD stones missed by MRCP, especially the small ones or those impacted at the distal CBD or the papillary region.

***Research objectives***

To evaluate the accuracy of EUS in detecting CBD stones missed by MRCP.

***Research methods***

Patients with an intermediate likelihood of choledocholithiasis according to ESGE guidelines and those with acute pancreatitis of undetermined cause were included. The presence of choledocholithiasis was evaluated by MRCP and EUS, and then results were confirmed by endoscopic retrograde cholangiopancreatography (ERCP). The sensitivity and specificity of EUS and MRCP were compared regarding the presence of stones, the size, and the number of detected stones.

***Research results***

Ninety out of 100 involved patients had choledocholithiasis, while ten patients were excluded as they had pancreatic or gall bladder masses during EUS examination. In choledocholithiasis patients, the mean age was 52.37 ± 14.64 years, and 52.2% were males. Most patients had biliary obstruction (74.4%), while only 23 (25.6%) patients had unexplained pancreatitis. The overall prevalence of choledocholithiasis was 83.3% by EUS, 41.1% by MRCP, and 74.4% by ERCP. Also, the number and size of CBD stones could be detected accurately in 78.2% and 75.6% by EUS and 41.1% and 70.3% by MRCP, respectively. The sensitivity of EUS was higher than that of MRCP (98.51% *vs* 55.22%), and their predictive value was statistically different (*P <* 0.001). Combination of both tools raised the sensitivity to 97.22% and specificity to 100%.

***Research conclusions***

EUS could be a useful tool in assessing patients with suspected choledocholithiasis especially if combined with MRCP. However, its usefulness depends on its availability and the experience of the local centers.

***Research perspectives***

EUS could be a good first option for evaluating patients with an intermediate probability of choledocholithiasis when it is available with good experience. Combining EUS with MRCP is recommended for accurate evaluation of patients with an intermediate probability of choledocholithiasis if both are available.

**ACKNOWLEDGEMENTS**

We would like to acknowledge our great hospital, and its workers, nurses, and staff members, for all the support and help in this study and throughout our careers.

**REFERENCES**

1 **Stinton LM**, Myers RP, Shaffer EA. Epidemiology of gallstones. *Gastroenterol Clin North Am* 2010; **39**: 157-169, vii [PMID: 20478480 DOI: 10.1016/j.gtc.2010.02.003]

2 **Collins C**, Maguire D, Ireland A, Fitzgerald E, O'Sullivan GC. A prospective study of common bile duct calculi in patients undergoing laparoscopic cholecystectomy: natural history of choledocholithiasis revisited. *Ann Surg* 2004; **239**: 28-33 [PMID: 14685097 DOI: 10.1097/01.sla.0000103069.00170.9c]

3 **Gurusamy KS,** Giljaca V, Takwoingi Y. Ultrasound vs liver function tests for diagnosis of common bile duct stones. *Cochrane Database Syst Rev* 2015; **2015**: CD011548 [DOI: 10.1002/14651858.cd011548]

4 **Schmidt S**, Chevallier P, Novellas S, Gelsi E, Vanbiervliet G, Tran A, Schnyder P, Bruneton JN. Choledocholithiasis: repetitive thick-slab single-shot projection magnetic resonance cholangiopancreaticography versus endoscopic ultrasonography. *Eur Radiol* 2007; **17**: 241-250 [PMID: 16941091 DOI: 10.1007/s00330-006-0380-5]

5 **Richard F**, Boustany M, Britt LD. Accuracy of magnetic resonance cholangiopancreatography for diagnosing stones in the common bile duct in patients with abnormal intraoperative cholangiograms. *Am J Surg* 2013; **205**: 371-373 [PMID: 23518180 DOI: 10.1016/j.amjsurg.2012.07.033]

6 **Manes G**, Paspatis G, Aabakken L, Anderloni A, Arvanitakis M, Ah-Soune P, Barthet M, Domagk D, Dumonceau JM, Gigot JF, Hritz I, Karamanolis G, Laghi A, Mariani A, Paraskeva K, Pohl J, Ponchon T, Swahn F, Ter Steege RWF, Tringali A, Vezakis A, Williams EJ, van Hooft JE. Endoscopic management of common bile duct stones: European Society of Gastrointestinal Endoscopy (ESGE) guideline. *Endoscopy* 2019; **51**: 472-491 [PMID: 30943551 DOI: 10.1055/a-0862-0346]

7 **ASGE Standards of Practice Committee**, Buxbaum JL, Abbas Fehmi SM, Sultan S, Fishman DS, Qumseya BJ, Cortessis VK, Schilperoort H, Kysh L, Matsuoka L, Yachimski P, Agrawal D, Gurudu SR, Jamil LH, Jue TL, Khashab MA, Law JK, Lee JK, Naveed M, Sawhney MS, Thosani N, Yang J, Wani SB. ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasis. *Gastrointest Endosc* 2019; **89**: 1075-1105.e15 [PMID: 30979521 DOI: 10.1016/j.gie.2018.10.001]

8 **Giljaca V,** Gurusamy KS, Takwoingi Y. Endoscopic ultrasound vs magnetic resonance cholangiopancreatography for common bile duct stones. *Cochrane Database Syst Rev* 2015; **2015**: CD011549 [DOI: 10.1002/14651858.CD011549]

9 **Gonzalo-Marin J**, Vila JJ, Perez-Miranda M. Role of endoscopic ultrasound in the diagnosis of pancreatic cancer. *World J Gastrointest Oncol* 2014; **6**: 360-368 [PMID: 25232461 DOI: 10.4251/wjgo.v6.i9.360]

10 **Rana SS**, Bhasin DK, Sharma V, Rao C, Gupta R, Singh K. Role of endoscopic ultrasound in evaluation of unexplained common bile duct dilatation on magnetic resonance cholangiopancreatography. *Ann Gastroenterol* 2013; **26**: 66-70 [PMID: 24714761]

11 **Patel R**, Ingle M, Choksi D, Poddar P, Pandey V, Sawant P. Endoscopic Ultrasonography Can Prevent Unnecessary Diagnostic Endoscopic Retrograde Cholangiopancreatography Even in Patients with High Likelihood of Choledocholithiasis and Inconclusive Ultrasonography: Results of a Prospective Study. *Clin Endosc* 2017; **50**: 592-597 [PMID: 28793395 DOI: 10.5946/ce.2017.010]

12 **Wee D**, Izard S, Grimaldi G, Raphael KL, Lee TP, Trindade AJ. EUS assessment for intermediate risk of choledocholithiasis after a negative magnetic resonance cholangiopancreatography. *Endosc Ultrasound* 2020; **9**: 337-344 [PMID: 33106466 DOI: 10.4103/eus.eus\_57\_20]

13 **Jagtap N**, Kumar JK, Chavan R, Basha J, Tandan M, Lakhtakia S, Kalapala R, Nabi Z, Gupta R, Ramchandani M, Talukdar R, Reddy M, Yarlagadda R, Singh J, Memon SF, Venkat Rao G, Reddy DN. EUS versus MRCP to perform ERCP in patients with intermediate likelihood of choledocholithiasis: a randomised controlled trial. *Gut* 2022 [PMID: 35144973 DOI: 10.1136/gutjnl-2021-325080]

14 **Meeralam Y**, Al-Shammari K, Yaghoobi M. Diagnostic accuracy of EUS compared with MRCP in detecting choledocholithiasis: a meta-analysis of diagnostic test accuracy in head-to-head studies. *Gastrointest Endosc* 2017; **86**: 986-993 [PMID: 28645544 DOI: 10.1016/j.gie.2017.06.009]

15 **de Lédinghen V**, Lecesne R, Raymond JM, Gense V, Amouretti M, Drouillard J, Couzigou P, Silvain C. Diagnosis of choledocholithiasis: EUS or magnetic resonance cholangiography? A prospective controlled study. *Gastrointest Endosc* 1999; **49**: 26-31 [PMID: 9869719 DOI: 10.1016/s0016-5107(99)70441-4]

16 **Materne R**, Van Beers BE, Gigot JF, Jamart J, Geubel A, Pringot J, Deprez P. Extrahepatic biliary obstruction: magnetic resonance imaging compared with endoscopic ultrasonography. *Endoscopy* 2000; **32**: 3-9 [PMID: 10691265 DOI: 10.1055/s-2000-86]

17 **Scheiman JM**, Carlos RC, Barnett JL, Elta GH, Nostrant TT, Chey WD, Francis IR, Nandi PS. Can endoscopic ultrasound or magnetic resonance cholangiopancreatography replace ERCP in patients with suspected biliary disease? A prospective trial and cost analysis. *Am J Gastroenterol* 2001; **96**: 2900-2904 [PMID: 11693324 DOI: 10.1111/j.1572-0241.2001.04245.x]

18 **Irie H**, Honda H, Kuroiwa T, Yoshimitsu K, Aibe H, Shinozaki K, Masuda K. Pitfalls in MR cholangiopancreatographic interpretation. *Radiographics* 2001; **21**: 23-37 [PMID: 11158641 DOI: 10.1148/radiographics.21.1.g01ja0523]

19 **Ney MV**, Maluf-Filho F, Sakai P, Zilberstein B, Gama-Rodrigues J, Rosa H. Echo-endoscopy versus endoscopic retrograde cholangiography for the diagnosis of choledocholithiasis: the influence of the size of the stone and diameter of the common bile duct. *Arq Gastroenterol* 2005; **42**: 239-243 [PMID: 16444379 DOI: 10.1590/s0004-28032005000400009]

20 **Aubé C**, Delorme B, Yzet T, Burtin P, Lebigot J, Pessaux P, Gondry-Jouet C, Boyer J, Caron C. MR cholangiopancreatography versus endoscopic sonography in suspected common bile duct lithiasis: a prospective, comparative study. *AJR Am J Roentgenol* 2005; **184**: 55-62 [PMID: 15615951 DOI: 10.2214/ajr.184.1.01840055]

21 **Ortega AR**, Gómez-Rodríguez R, Romero M, Fernández-Zapardiel S, Céspedes Mdel M, Carrobles JM. Prospective comparison of endoscopic ultrasonography and magnetic resonance cholangiopancreatography in the etiological diagnosis of "idiopathic" acute pancreatitis. *Pancreas* 2011; **40**: 289-294 [PMID: 21206330 DOI: 10.1097/MPA.0b013e318201654a]

22 **Wan J**, Ouyang Y, Yu C, Yang X, Xia L, Lu N. Comparison of EUS with MRCP in idiopathic acute pancreatitis: a systematic review and meta-analysis. *Gastrointest Endosc* 2018; **87**: 1180-1188.e9 [PMID: 29225082 DOI: 10.1016/j.gie.2017.11.028]

23 **Wilcox CM**, Seay T, Kim H, Varadarajulu S. Prospective Endoscopic Ultrasound-Based Approach to the Evaluation of Idiopathic Pancreatitis: Causes, Response to Therapy, and Long-term Outcome. *Am J Gastroenterol* 2016; **111**: 1339-1348 [PMID: 27325219 DOI: 10.1038/ajg.2016.240]

24 **Mustafa Zanyar Akkuzu,** Engin Altıntaş, Serkan Yaraş, Osman Özdoğan, Enver Ucbilek, Fehmi Ates, Orhan Sezgin, Ferzan Aydın, Hatice Rızaoğlu Balcı, Yaren Dirik. EUS accuracy against MRCP for detection of pancreaticobiliary lesions. *Eastern J Med* 2020; **25**: 535-539 [DOI: 10.5505/ejm.2020.92195]

**Footnotes**

**Institutional review board statement:** Our institution’s Research Ethical Committee approved the study, and all patients gave their informed written consent before inclusion in the study, according to the ethical guidelines of the 1975 Declaration of Helsinki. The National Liver Institute IRB protocol number is 00305/2022.

**Clinical trial registration statement:** The clinical trial is registered with Brazilian Clinical Trials Registry (ReBec).

**Informed consent statement:** All study participants, or their legal guardian, provided written consent prior to study enrollment.

**Conflict-of-interest statement:** All authors declare that they have no conflict of interest to disclose.

**Data sharing statement:** No additional data are available.

**CONSORT 2010 statement:** The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** June 2, 2022

**First decision:** July 12, 2022

**Article in press:** September 6, 2022

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Egypt

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C, C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Er LM, China; Pelaez-Luna M, Mexico **S-Editor:** Wang LL **L-Editor:** Wang TQ **P-Editor:** Wang LL

**Figure Legends**



**Figure 1 Flow chart of the studied patients.** MRCP: Magnetic resonance cholangiopancreatography: EUS: Endoscopic ultrasound; ERCP: Endoscopic Retrograde Cholangiopancreatography.



**Figure 2 Comparison of sensitivity and specificity of endoscopic ultrasound and magnetic resonance cholangiopancreatography in detecting choledocholithiasis.** EUS: Endoscopic ultrasound; MRCP: Magnetic resonance cholangiopancreatography.



**Figure 3 Two distal common bile duct stones as seen from the gastric body.** CBD: Common bile duct.



**Figure 4 A small soft non-shadowing common bile duct stone as seen from the bulb of the duodenum.** CBD: Common bile duct.



**Figure 5 An impacted stone in the region of the major papilla as seen in the mid-second part of the duodenum.**

**Table 1 Biochemical data of the included patients**

|  |  |  |
| --- | --- | --- |
|  | ***n*** | **%** |
| Alanine transaminase, aspartate aminotransferase | Up to 33 U/L | |
| Normal | 36 | 40.0 |
| < 3 fold | 44 | 48.9 |
| ≥ 3 fold | 10 | 11.1 |
| Bilirubin | Up to 1.1 mg/dL | |
| Normal | 17 | 18.9 |
| Yes | 73 | 81.1 |
| < 5 mg/100 mL | 54 | 74.0 |
| ≥ 5 mg/100 mL | 19 | 26.0 |
| Min-Max | 1.40-20.0 | |
| mean ± SD | 3.99 ± 3.30 | |
| Median (IQR) | 3.0 (2.0-5.0) | |
| Alkaline phosphatase | 35-104 U/L | |
| GGT | Up to 40 U/L | |
| Normal | 7 | 7.8 |
| < 3 fold | 24 | 26.7 |
| ≥ 3 fold | 59 | 65.6 |

IQR: Interquartile range; GGT: Gamma glutamyl transpeptidase.

**Table 2 Cases of choledocholithiasis detected by endoscopic ultrasound**

|  |  |  |
| --- | --- | --- |
| **Common bile duct stones detected by endoscopic ultrasound** | **Patients (*n*)** | **%** |
| Common bile duct stones detected by endoscopic ultrasound |  |  |
| No | 15 | 16.7 |
| Yes | 75 | 83.3 |
| Stones (*n*) |  |  |
| No stones | 20 | 22.2 |
| 1 | 42 | 46.7 |
| 2 | 12 | 13.3 |
| 3 | 5 | 5.6 |
| 4 | 1 | 1.1 |
| 5 | 1 | 1.1 |
| 6 | 1 | 1.1 |
| Multiple | 8 | 8.9 |
| Size of stones (mm) |  |  |
| No stones | 20 | 22.2 |
| Gravels (1-2 mm) | 2 | 2.2 |
| 3-5 | 25 | 27.8 |
| > 5 | 43 | 47.8 |

**Table 3 Accuracy, sensitivity, and specificity of endoscopic ultrasound and magnetic resonance cholangiopancreatography in detecting choledocholithiasis**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Endoscopic retrograde cholangiopancreatography findings** | | | | **Sensitivity** | **Specificity** | **PPV** | **NPV** | **Accuracy** |
| **No (*n* = 23)** |  | **Yes (*n* = 67)** |  |
| CBD stones detected by EUS | *n* | % | *n* | % |  |  |  |  |  |
| No | 14 | 60.9 | 1 | 1.5 | 98.51 | 60.87 | 88.0 | 93.33 | 88.89 |
| Yes | 9 | 39.1 | 66 | 98.5 |
| FE*P* value | 43.464 (< 0.001) |  |  |  |  |  |  |  |  |
| MRCP stones | *n* | % | *n* | % |  |  |  |  |  |
| No | 23 | 100.0 | 30 | 44.8 |  |  |  |  |  |
| Yes | 0 | 0.0 | 37 | 55.2 | 55.22 | 100.0 | 100.0 | 43.40 | 66.67 |
| *P* value | 21.569 (< 0.001) |  |  |  |  |  |  |  |  |

PPV: Positive predictive value; NPV: Negative predictive value; CBD: Common bile duct; EUS: Endoscopic ultrasound; MRCP: Magnetic resonance cholangiopancreatography; ERCP: Endoscopic retrograde cholangiopancreatography.

**Table 4 Agreement (sensitivity, specificity, and accuracy) for combined endoscopic ultrasound and magnetic resonance cholangiopancreatography**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Combined EUSMRCP** | **ERCP findings** | | | | **Sensitivity** | **Specificity** | **PPV** | **NPV** | **Accuracy** |
| **No (*n* = 11)** |  | **Yes (*n* = 36)** |  |
| ***n*** | **%** | ***n*** | **%** |
| No | 11 | 100.0 | 1 | 2.8 | 97.22 | 100.0 | 100.0 | 91.67 | 97.87 |
| Yes | 0 | 0.0 | 35 | 97.2 |
| FE*P* value | 41.887 (< 0.001) | | | |  |  |  |  |  |

PPV: Positive predictive value; NPV: Negative predictive value; EUS: Endoscopic ultrasound; MRCP: Magnetic resonance cholangiopancreatography; ERCP: Endoscopic retrograde cholangiopancreatography.

**Table 5 Differences in endoscopic skill between expert and non-expert endoscopists**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **CBD stones detected by EUS** | **Total (*n* = 90)** | | | | | **Non-expert (*n* = 27)** | | **Expert (*n* = 63)** | |
| ***n*** | | | | **%** | ***n*** | **%** | ***n*** | **%** |
| No | 15 | | | | 16.7 | 11 | 40.7 | 4 | 6.3 |
| Yes | 75 | | | | 83.3 | 16 | 59.3 | 59 | 93.7 |
| Number |  | | | |  |  |  |  |  |
| No. | 20 | | | | 22.2 | 14 | 51.9 | 6 | 9.5 |
| 1 | 42 | | | | 46.7 | 8 | 29.6 | 34 | 54.0 |
| 2 | 12 | | | | 13.3 | 2 | 7.4 | 10 | 15.9 |
| 3 | 5 | | | | 5.6 | 0 | 0.0 | 5 | 7.9 |
| 4 | 1 | | | | 1.1 | 0 | 0.0 | 1 | 1.6 |
| 5 | 1 | | | | 1.1 | 0 | 0.0 | 1 | 1.6 |
| 6 | 1 | | | | 1.1 | 0 | 0.0 | 1 | 1.6 |
| Multiple | 8 | | | | 8.9 | 3 | 11.1 | 5 | 7.9 |
| Size (mm) |  | | | |  |  |  |  |  |
| No. | 22 | | | | 24.4 | 14 | 51.9 | 8 | 12.7 |
| ≤ 5 | 25 | | | | 27.8 | 4 | 14.8 | 21 | 33.3 |
| > 5 | 43 | | | | 47.8 | 9 | 33.3 | 34 | 54.0 |
| Other findings of EUS |  | | | |  |  |  |  |  |
| No | 65 | | | | 72.2 | 14 | 51.9 | 51 | 81.0 |
| Yes | 25 | | | | 27.8 | 13 | 48.1 | 12 | 19.0 |
|  | ERCP findings | | | | Sensitivity | Specificity | PPV | NPV | Accuracy |
|  | No | | Yes | |  |  |  |  |  |
|  | *n* | % | *n* | % |  |  |  |  |  |
| Total sample (*n =* 90) | *n* = 23 |  | *n* = 67 |  |  |  |  |  |  |
| No | 14 | 60.9 | 1 | 1.5 |  |  |  |  |  |
| Yes | 9 | 39.1 | 66 | 98.5 | 98.51 | 60.87 | 88.0 | 93.33 | 88.89 |
| FE*P* value | 43.464 (< 0.001) |  |  |  |  |  |  |  |  |
| Non-expert (*n =* 27) | *n =* 13 |  | *n =* 14 |  |  |  |  |  |  |
| No | 10 | 76.9 | 1 | 7.1 |  |  |  |  |  |
| Yes | 3 | 23.1 | 13 | 92.9 | 92.86 | 76.92 | 81.25 | 90.91 | 85.19 |
| FE*P* value | 13.595(< 0.001) |  |  |  |  |  |  |  |  |
| Expert (*n =* 63) | *n =* 10 |  | *n =* 53 |  |  |  |  |  |  |
| No | 4 | 40.0 | 0 | 0.0 |  |  |  |  |  |
| Yes | 6 | 60.0 | 53 | 100.0 | 100.0 | 40.0 | 89.83 | 100.0 | 90.48 |
| FE*P* value | 22.637(< 0.001) |  |  |  |  |  |  |  |  |

PPV: Positive predictive value; NPV: Negative predictive value; EUS: Endoscopic ultrasound; MRCP: Magnetic resonance cholangiopancreatography; ERCP: Endoscopic retrograde cholangiopancreatography.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**